Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Navidea Biopharmaceuticals, Inc. Common Stock (NY: NAVB )

N/A UNCHANGED
Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Navidea Biopharmaceuticals, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
Navidea Biopharmaceuticals Files Appeal in CRG Case
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 236 companies set new 52-week lows. 
Via Benzinga
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares! 
Via InvestorPlace
Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket
Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split. 
Via Benzinga
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Short Volatility Alert: Navidea Biopharmaceuticals, Inc.
On Tuesday, shares of Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) experienced volatile short activity. After the activity, the stock price went up +0.00% to $0.39. The overall sentiment for NAVB has... 
Via Benzinga
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 37 stocks hit new 52-week lows. 
Via Benzinga
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.